Video Information | Nuvaring Pulmonary Embolism | Nuva ring PE Stroke Class Action

by Steve Fields on August 16th, 2008

The number of women around the country suffering from Nuvaring pulmonary embolism and blood clots continues to increase. One of the most serious Nuva ring side effects is a higher risk of venous thrombosis (blood clots), which could lead to a stroke or heart attack. Studies have shown a link between desogestrel and a higher risk of blood clots and stroke. NuvaRing has been associated with blood clots including deep vein thrombosis, pulmonary embolism, as well as stroke and heart attack.

NuvaRing is a flexible, transparent, birth control ring that is about two inches in diameter. It is inserted into the vagina and left for three weeks until it is taken out. After one week, during which time the menstrual cycle bleeding usually occurs, a new NuvaRing is inserted for another three-weeks. NuvaRing’s position in the vagina is not critical for its function.

NuvaRing is made by Organon USA. Organon USA is a pharmaceutical company owned by the multi-national conglomerate Akzo Nobel, which is headquartered in the Netherlands. NuvaRing was first approved in the Netherlands in February 2001. On October 3, 2001, NuvaRing was approved in the United States by the Food and Drug Administration (FDA).

NuvaRing releases two types of hormones – an estrogen and a progestin. It is a third generation birth control that incorporates a different form of progestin than older contraceptives called desogestrel. The vaginal walls absorb the hormones and release them into the bloodstream. The hormones are designed to prevent the ovaries from producing mature eggs. Also, the lining of the uterus becomes thinner which obstructs implantation of a fertilized egg.

The following video describes a pulmonary embolism.

VideoJug: What is a “pulmonary embolism”?

If you have suffered from a Nuva ring pulmonary embolism or blood clot please contact us by calling or via e-mail for a free consultation from a Nuva ring attorney.